MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction (MAGSTEMI)
MAGnesium-based Bioresorbable Scaffold and Vasomotor Function in Patients With Acute ST Segment Elevation Myocardial Infarction
Sponsor: Hospital Clinic of Barcelona
This PHASE3 trial investigates Acute Coronary Syndrome and ST Segment Elevation Myocardial Infarction and is currently completed. Hospital Clinic of Barcelona leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
May 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Aug 2019 — May 2020 [monthly]
Recruiting PHASE3
Phase: PHASE2_PHASE3 → PHASE3
▶ Show 4 earlier versions
-
May 2019 — Aug 2019 [monthly]
Recruiting PHASE2_PHASE3
Status: Active Not Recruiting → Recruiting
-
Aug 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hospital Clinic of Barcelona
- Spanish Society of Cardiology
For direct contact, visit the study record on ClinicalTrials.gov .